In addition to blocking VEGFR2, YLL545 altered the expression of other molecules involved in tumor angiogenesis, including ITGAV [30], ENG [31, 32], THBS1 [33, 34], FN1 [35–37], and TEK [38, 39]. The gene discussed is KDR; the disease is neoplasm.